Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

160.93USD
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
$160.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
780,233
52-wk High
$197.00
52-wk Low
$114.27

Select another date:

Tue, Aug 20 2019

UPDATE 2-Drugmakers Endo, Allergan agree to $15 mln in settlements in major opioid case

Aug 20 Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.

UPDATE 1-Evolus reports sales of its Botox rival ahead of expectations

Aug 12 Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Aug 12 Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc , which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Aug 6 Allergan Plc, which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane

July 26 AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

Allergan recalls textured breast implants worldwide

Allergan Plc said on Wednesday it was recalling its Biocell textured breast implants and tissue expanders across markets, citing concerns over a rare form of cancer, after the U.S. health agency asked the drugmaker to pull the products.

UPDATE 3-Allergan recalls textured breast implants worldwide

July 24 Allergan Plc said on Wednesday it was recalling its Biocell textured breast implants and tissue expanders across markets, citing concerns over a rare form of cancer, after the U.S. health agency asked the drugmaker to pull the products.

Select another date: